{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:15:27Z","timestamp":1789654527779,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02177-5","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T02:37:06Z","timestamp":1779331026000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prediction of mRECIST tumor response at firstfollow-up after DEB-TACE using a combined radiomics-clinical model and explainability methods"],"prefix":"10.1007","volume":"26","author":[{"given":"Jiayi","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongxing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"L\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"issue":"10127","key":"2177_CR1","first-page":"1301","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner A, Reig M, Bruix J. Hepatocellular carcinoma Lancet. 2018;391(10127):1301\u201314.","journal-title":"Hepatocellular carcinoma Lancet"},{"issue":"12","key":"2177_CR2","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","volume":"20","author":"AG Singal","year":"2023","unstructured":"Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol. 2023;20(12):864\u201384.","journal-title":"Nat Rev Clin Oncol"},{"key":"2177_CR3","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182\u2013236."},{"issue":"1","key":"2177_CR4","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach JK, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358\u201380.","journal-title":"Hepatology"},{"issue":"2","key":"2177_CR5","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723\u201350.","journal-title":"Hepatology"},{"issue":"1","key":"2177_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5009\/gnl.2013.7.1.89","volume":"7","author":"DS Song","year":"2013","unstructured":"Song DS, et al. DC Bead Transarterial Chemoembolization Is Effective in Hepatocellular Carcinoma Refractory to Conventional Transarteral Chemoembolization: A Pilot Study. Gut Liver. 2013;7(1):89\u201395.","journal-title":"Gut Liver"},{"issue":"4","key":"2177_CR7","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3350\/cmh.2015.21.4.344","volume":"21","author":"HY Woo","year":"2015","unstructured":"Woo HY, Heo J. Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and future. Clin Mol Hepatol. 2015;21(4):344\u20138.","journal-title":"Clin Mol Hepatol"},{"issue":"40","key":"2177_CR8","doi-asserted-by":"publisher","first-page":"8853","DOI":"10.3748\/wjg.v22.i40.8853","volume":"22","author":"HC Nam","year":"2016","unstructured":"Nam HC, Jang B, Song MJ. Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma. World J Gastroenterol. 2016;22(40):8853\u201361.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"2177_CR9","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1159\/000365993","volume":"87","author":"S Ogasawara","year":"2014","unstructured":"Ogasawara S, et al. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. Oncology. 2014;87(6):330\u201341.","journal-title":"Oncology"},{"issue":"4","key":"2177_CR10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1159\/000367743","volume":"4","author":"T Arizumi","year":"2015","unstructured":"Arizumi T, et al. Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma. Liver Cancer. 2015;4(4):253\u201362.","journal-title":"Liver Cancer"},{"issue":"8","key":"2177_CR11","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.1364\/BOE.9.003783","volume":"9","author":"H Lin","year":"2018","unstructured":"Lin H, et al. Label-free classification of hepatocellular-carcinoma grading using second harmonic generation microscopy. Biomed Opt Express. 2018;9(8):3783\u201393.","journal-title":"Biomed Opt Express"},{"issue":"12","key":"2177_CR12","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","volume":"14","author":"P Lambin","year":"2017","unstructured":"Lambin P, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14(12):749\u201362.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"2177_CR13","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/annonc\/mdx034","volume":"28","author":"EJ Limkin","year":"2017","unstructured":"Limkin EJ, et al. Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology. Ann Oncol. 2017;28(6):1191\u2013206.","journal-title":"Ann Oncol"},{"issue":"1","key":"2177_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s11547-023-01736-0","volume":"129","author":"K Liu","year":"2024","unstructured":"Liu K, et al. A multi-institutional study to predict the benefits of DEB-TACE and molecular targeted agent sequential therapy in unresectable hepatocellular carcinoma using a radiological-clinical nomogram. Radiol Med. 2024;129(1):14\u201328.","journal-title":"Radiol Med"},{"issue":"1","key":"2177_CR15","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/hep.31022","volume":"72","author":"G Han","year":"2020","unstructured":"Han G, et al. Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. Hepatology. 2020;72(1):198\u2013212.","journal-title":"Hepatology"},{"issue":"4","key":"2177_CR16","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1007\/s00330-019-06553-6","volume":"30","author":"D Liu","year":"2020","unstructured":"Liu D, et al. Accurate prediction of responses to transarterial chemoembolization for patients with hepatocellular carcinoma by using artificial intelligence in contrast-enhanced ultrasound. Eur Radiol. 2020;30(4):2365\u201376.","journal-title":"Eur Radiol"},{"issue":"10","key":"2177_CR17","doi-asserted-by":"publisher","first-page":"7500","DOI":"10.1007\/s00330-021-07910-0","volume":"31","author":"C Kong","year":"2021","unstructured":"Kong C, et al. Prediction of tumor response via a pretreatment MRI radiomics-based nomogram in HCC treated with TACE. Eur Radiol. 2021;31(10):7500\u201311.","journal-title":"Eur Radiol"},{"issue":"8","key":"2177_CR18","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1007\/s00261-021-02992-2","volume":"46","author":"Y Kuang","year":"2021","unstructured":"Kuang Y, et al. MRI-Based Radiomics: Nomograms predicting the short-term response after transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma patients with diameter less than 5\u00a0cm. Abdom Radiol (NY). 2021;46(8):3772\u201389.","journal-title":"Abdom Radiol (NY)"},{"issue":"1","key":"2177_CR19","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s12876-022-02366-y","volume":"22","author":"P Ananchuensook","year":"2022","unstructured":"Ananchuensook P, et al. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization. BMC Gastroenterol. 2022;22(1):295.","journal-title":"BMC Gastroenterol"},{"issue":"10","key":"2177_CR20","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1007\/s00270-022-03221-z","volume":"45","author":"H Bai","year":"2022","unstructured":"Bai H, et al. Preoperative CECT-based Radiomic Signature for Predicting the Response of Transarterial Chemoembolization (TACE) Therapy in Hepatocellular Carcinoma. Cardiovasc Intervent Radiol. 2022;45(10):1524\u201333.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"2","key":"2177_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000520292","volume":"100","author":"A Hiraoka","year":"2022","unstructured":"Hiraoka A, et al. Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era. Oncology. 2022;100(2):65\u201373.","journal-title":"Oncology"},{"issue":"1","key":"2177_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52\u201360.","journal-title":"Semin Liver Dis"},{"issue":"6","key":"2177_CR23","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3904\/kjim.2018.058","volume":"34","author":"MY Baek","year":"2019","unstructured":"Baek MY, et al. Clinical outcomes of patients with a single hepatocellular carcinoma less than 5\u00a0cm treated with transarterial chemoembolization. Korean J Intern Med. 2019;34(6):1223\u201332.","journal-title":"Korean J Intern Med"},{"issue":"5","key":"2177_CR24","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1007\/s10637-022-01261-3","volume":"40","author":"H Lin","year":"2022","unstructured":"Lin H, et al. The efficacy of transarterial chemoembolization in downstaging unresectable hepatocellular carcinoma to curative therapy: a predicted regression model. Invest New Drugs. 2022;40(5):1146\u201352.","journal-title":"Invest New Drugs"},{"issue":"10","key":"2177_CR25","first-page":"4956","volume":"11","author":"CW Peng","year":"2021","unstructured":"Peng CW, et al. Complete response at first transarterial chemoembolization predicts favorable outcome in hepatocellular carcinoma. Am J Cancer Res. 2021;11(10):4956\u201365.","journal-title":"Am J Cancer Res"},{"issue":"5","key":"2177_CR26","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/bjc.2017.214","volume":"117","author":"L Jiang","year":"2017","unstructured":"Jiang L, et al. Platelet releasate promotes breast cancer growth and angiogenesis via VEGF-integrin cooperative signalling. Br J Cancer. 2017;117(5):695\u2013703.","journal-title":"Br J Cancer"},{"issue":"4","key":"2177_CR27","doi-asserted-by":"publisher","first-page":"452","DOI":"10.20892\/j.issn.2095-3941.2016.0059","volume":"13","author":"JX Sun","year":"2016","unstructured":"Sun JX, et al. Portal vein tumor thrombus is a bottleneck in the treatment of hepatocellular carcinoma. Cancer Biol Med. 2016;13(4):452\u20138.","journal-title":"Cancer Biol Med"},{"key":"2177_CR28","doi-asserted-by":"publisher","unstructured":"Ebeling Barbier C, Heindryckx F, Lennern\u00e4s H. Limitations and possibilities of transarterial chemotherapeutic treatment of hepatocellular carcinoma. Int J Mol Sci. 2021;22(23):13051. https:\/\/doi.org\/10.3390\/ijms222313051","DOI":"10.3390\/ijms222313051"},{"issue":"10","key":"2177_CR29","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1111\/jgh.15553","volume":"36","author":"KY Tak","year":"2021","unstructured":"Tak KY, et al. Use of M2BPGi in HCC patients with TACE. J Gastroenterol Hepatol. 2021;36(10):2917\u201324.","journal-title":"J Gastroenterol Hepatol"},{"issue":"8","key":"2177_CR30","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.addr.2011.04.002","volume":"63","author":"AS Narang","year":"2011","unstructured":"Narang AS, Varia S. Role of tumor vascular architecture in drug delivery. Adv Drug Deliv Rev. 2011;63(8):640\u201358.","journal-title":"Adv Drug Deliv Rev"},{"key":"2177_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2019.05.005","volume":"457","author":"V Potiron","year":"2019","unstructured":"Potiron V, et al. Tumor vasculature remodeling by radiation therapy increases doxorubicin distribution and efficacy. Cancer Lett. 2019;457:1\u20139.","journal-title":"Cancer Lett"},{"issue":"2","key":"2177_CR32","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1158\/0008-5472.CAN-05-3077","volume":"66","author":"R Grantab","year":"2006","unstructured":"Grantab R, Sivananthan S, Tannock IF. The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Cancer Res. 2006;66(2):1033\u20139.","journal-title":"Cancer Res"},{"issue":"7","key":"2177_CR33","doi-asserted-by":"publisher","first-page":"6126","DOI":"10.1021\/acsomega.2c06659","volume":"8","author":"PA Patkulkar","year":"2023","unstructured":"Patkulkar PA, et al. Mapping Spatiotemporal Heterogeneity in Tumor Profiles by Integrating High-Throughput Imaging and Omics Analysis. ACS Omega. 2023;8(7):6126\u201338.","journal-title":"ACS Omega"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02177-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02177-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02177-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T05:10:55Z","timestamp":1782537055000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02177-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2177"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02177-5","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"15 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Harbin Medical University(YJSKY2025-090).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Due to the retrospective design, the requirement for individual patient consent was waived by the reviewing ethics committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"Due to the retrospective design, the requirement for individual patient consent was waived by the reviewing ethics committee.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"240"}}